180 Life Sciences Corp Cash Flow Conversion Efficiency
180 Life Sciences Corp cash flow conversion efficiency. Based on the latest financial reports, 180 Life Sciences Corp (ATNF) has a cash flow conversion efficiency ratio of -0.037x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.30 Million) by net assets ($445.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of 180 Life Sciences Corp (2017–2024)
Cash flow conversion efficiency of 180 Life Sciences Corp from 2017 to 2024. This chart illustrates how 180 Life Sciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ATNF live share price for real-time trading data and today's change.
180 Life Sciences Corp Cash Flow Conversion Ratio Explained
180 Life Sciences Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
180 Life Sciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 180 Life Sciences Corp ranked by their cash flow conversion efficiency. Also see 180 Life Sciences Corp stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Loma Negra Compañía Industrial Argentina Sociedad Anónima
F:8LN
|
0.016x |
|
Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRI
|
0.053x |
|
SVG Optronics Co Ltd
SHE:300331
|
0.030x |
|
Arendals Fossekompani ASA
OL:AFK
|
0.013x |
|
Smartgroup Corporation Ltd
AU:SIQ
|
0.253x |
|
Shandong Lukang Pharmaceutical Co Ltd
SHG:600789
|
-0.001x |
|
Hunan Fazhan Industrial Co Ltd
SHE:000722
|
0.026x |
|
Oriental Holdings Bhd
KLSE:4006
|
0.060x |
Annual Cash Flow Conversion Efficiency for 180 Life Sciences Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of 180 Life Sciences Corp from 2017 to 2024. Review cash generation quality of 180 Life Sciences Corp to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.25 Million | $-1.48 Million | -0.160x | -100.19% |
| 2023-12-31 | $-127.73K | $-10.92 Million | 85.508x | +8098.28% |
| 2022-12-31 | $11.34 Million | $-12.13 Million | -1.069x | -985.73% |
| 2021-12-31 | $39.32 Million | $-3.87 Million | -0.098x | +22.98% |
| 2020-12-31 | $30.29 Million | $-3.87 Million | -0.128x | -48.58% |
| 2019-12-31 | $38.57 Million | $-3.32 Million | -0.086x | -183.69% |
| 2018-12-31 | $-7.68 Million | $-789.23K | 0.103x | +2432.13% |
| 2017-12-31 | $112.83 Million | $-497.36K | -0.004x | -- |
About 180 Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more